Evidence map›Paper›PMID 39001919›Full record

Trial reportEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2024

Efficacy of forskolin as a promising therapy for chronic olfactory dysfunction post COVID-19.

Mohamed H Abdelazim, Faisal Alsenani, Mohammed Alnuhait, Abdullah S Alshammari, Abdullah H Altemani, Eyad A Althagafi, Dania S Waggas, Ahmed H Abdelazim, Adnan Alharbi

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mohamed H AbdelazimDepartment of Otolaryngology, Faculty of Medicine, Al-Azhar University, Damietta, Egypt.
Faisal AlsenaniDepartment of Pharmaceutical Sciences, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Mohammed AlnuhaitPharmaceutical Practices Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Abdullah S AlshammariPharmaceutical Practices Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Abdullah H AltemaniDepartment of Family and Community Medicine, Faculty of Medicine, University of Tabuk, Tabuk, Saudi Arabia.
Eyad A AlthagafiDepartment of pharmaceutical care, King Fahad General Hospital, Jeddah, Saudi Arabia.
Dania S WaggasDepartment of Pathological Sciences, Fakeeh College for Medical Sciences, Jeddah, Saudi Arabia.
Ahmed H AbdelazimPharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt. ahmed.hussienabdelazim@hotmail.com.ORCID http://orcid.org/0000-0002-8907-3497
Adnan AlharbiPharmaceutical Practices Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOlfactory dysfunction is increasingly common among COVID-19 patients, impacting their well-being. Reports have demonstrated decreased levels of cyclic adenosine monophosphate and cyclic guanosine monophosphate among patients with chronic olfactory dysfunction. A prospective randomized clinical trial was developed to demonstrate the efficacy of an oral forskolin regimen treatment, an adenylyl cyclase activator that raises intracellular levels of cyclic adenosine monophosphate, for the treatment of olfactory dysfunction following COVID-19, compared to placebo regimen.

methodsThe study enrolled 285 participants with persistent olfactory dysfunction post COVID-19 infection, randomly assigning them to receive either placebo capsules (n = 120) or oral forskolin capsules (n = 165). Follow-up was conducted to track progress, with 18 participants from the placebo group and 12 from the forskolin group lost during this period. Olfactory function was assessed using the "Sniffin' Sticks" test, measuring threshold, discrimination and identification scores before and after treatment.

resultsSubjects administered forskolin capsules demonstrated a significant enhancement in their composite TDI (threshold, discrimination and identification) score, suggesting a notable amelioration in olfactory functionality. Moreover, the discrimination and identification scores notably improved within the forskolin group. Conversely, no significant alterations were observed in the threshold scores.

conclusionThis study suggests that forskolin can contribute potentially to improve chronic olfactory dysfunction post COVID-19.

trial registrationDFM-IRB00012367-23-10-001.

Indexed as

ColforsinCOVID-19Olfaction DisordersAdultAgedChronic DiseaseDouble-Blind MethodFemaleHumansMaleMiddle AgedProspective StudiesSARS-CoV-2Treatment OutcomeColforsinAdenylyl cyclaseClinical studyForskolinOlfactory dysfunctionSniffin’ sticks

Identifiers

PMID39001919

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.